Biopharmaceutical company putting patients at the heart of what we do, using our unique model to improve the technology, awareness and access to cannabis based medicines.
The UK & Ireland's leading medical cannabis importer, bringing affordable pharma-quality cannabis medicines to patients globally, and educating and empowering doctors.
R&D division focused on bringing down costs of manufacturing and increasing the quality of medicines.
The world's first medical cannabis trading company, providing solutions to develop an uninterrupted supply chain.
Grow is a biopharmaceutical company focused solely on cannabis based medicines and improving global access to those medicines.
Grow exists to deliver quality cannabis medicines to the patients that need them.
Grow seeks to be the world's leading supplier of medical cannabis to patients by 2025.
To do this we innovate and solve fundamental industry issues in order to bring affordable pharma quality cannabis medicines to patients globally, and we empower and educate doctors to make the correct medical cannabis prescribing decisions.
OUR COMPETITIVE ADVANTAGE
1.
UNIQUE
UNDERSTANDING
of the medical cannabis supply chain and how to improve patient outcomes with cannabis medicines.
2.
LEADERSHIP
TEAM
of pharma professionals, scientists, bankers and commodity traders.
3.
DEEP
EXPERTISE
combined with a relentless drive to solve the problems the industry and patients face.
4.
LOGISTICAL-
PARTNERSHIPS
Grow differentiates itself by negating the need to spend hundreds of millions on hard assets through effective partnerships.
Grow Group is current raising a Series C Pre-IPO round
We are proud to offer high net worth and sophisticated investors the chance to join the Grow family via our Series C raise which launched in November 2020.
We are seeking £6 million in total via EIS eligible equity and/ or a convertible loan instrument. These funds will be used to expand Grow's highly successful model at this pivotal time in the medical cannabis industry.
For more information please contact [email protected].
* This opportunity is for sophisticated and high net worth investors only.
